MedPath

Ketogenic Diet as Protective Factor During COVID-19

Not Applicable
Conditions
Covid19
Interventions
Dietary Supplement: Ketogenic diet with phytoextracts
Registration Number
NCT04615975
Lead Sponsor
University of Padova
Brief Summary

The novel coronavirus disease (COVID-19) is posing a serious challenge to the health-care systems worldwide, with an enormous impact on health conditions and loss of lives. More than 30 millions of recoveries worldwide were registered at the end of October 2020 with more than 1 million of deaths. As the disease continues to spread, strategies aimed to reduce hospitalization time in sub intensive unit care, thus reducing pressure on health system, but also to reduce some of the pathological features of COVID-19 such as inflammation and the "cytokines storm".

The ketogenic diet is a high fat, low carbohydrate, adequate-protein diet that promotes a physiological ketosis (due to an increase of liver ketone bodies production). High fat, low carbohydrate diets have been shown to reduce duration of ventilator support and partial pressure carbon dioxide in patients with acute respiratory failure. Moreover, the physiological increase in plasma levels of ketone bodies exerts important anti-inflammatory and immunomodulating effects, which may reveal as precious tools to reduce potential adverse outcomes of COVID-19 disease.

The hypothesis of this study is that the administration of a ketogenic diet will improve gas exchange, reduce inflammation, and the duration of hospitalization. The plan is to enrol 28 patients with diagnosis of COVID-19 hospitalized but not in ICU with SPO2 higher than 88%.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
28
Inclusion Criteria
  • Patients hospitalized Hospital with COVID-19 diagnosis (nasopharyngeal and oropharyngeal swab)
  • peripheral oxygen saturation higher tha 88%
Exclusion Criteria
  • intensive unit care
  • under forced ventilation
  • peripheral oxygen saturation lower than 88%
  • parenteral nutrition

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
InterventionKetogenic diet with phytoextractsPatients will receive 21 days of a very low carbohydrate mediterranean ketogenic diet with phytoextracts and 7 days of a low carbohydrate diet
Primary Outcome Measures
NameTimeMethod
The total hospital stayup to 30 days

Time from hospital admission to discharge from the hospital.

inflammation panel: tumor necrosis factor alfa (TNFα)Daily untilpatient's hospital discharge, up to 30 days

change in TNFα levels. TNFα is an inflammatory cytokine Units: pg/mL

inflammation panel: C-reactive Protein (CRP)Daily until patient's hospital discharge, up to 30 days

change in CRP levels. CRP is an non specific index of inflammation Units: in mg/dL

inflammation panel: Erythrocyte sedimentation rate (ESR)Daily untilpatient's hospital discharge, up to 30 days

change in ESR. ESR is an non specific index of inflammationUnits: mm/h

coagulation panel: fibrinogenDaily until patient's hospital discharge, up to 30 days

change in fibrinogen levels. Fibrinogen is a protein involved in forming blood clots in the body. Units: mg/dL

coagulation panel: thrombin clotting time (TT)Daily until patient's hospital discharge, up to 30 days

change in TT. TT measures the time it takes for a clot to form in the plasma of a blood sample containing anticoagulant, after an excess of thrombin has been added. Units: seconds

coagulation panel: activated partial thromboplastin time (aPTT)Daily until patient's hospital discharge, up to 30 days

change inl aPTT. aPTT measures the overall speed at which blood clots by means of two consecutive series of biochemical reactions. Units: in seconds

inflammation panel: interleukine 6 (IL-6)Daily until patient's hospital discharge, up to 30 days

change in IL-6 levels. IL-6 is an inflammatory cytokine. Units: in pg/mL

coagulation panel: D-DimerDaily until patient's hospital discharge, up to 30 days

change in D-Dimer levels. D-Dimer is a fibrin degradation product. Units: 0.5 mcg/ml Fibrinogen Equivalent Units (FEU)

Dyspnoea Visual Analog Scale Score (VAS)Daily until patient's hospital discharge, up to 30 days

Change in VAS. VAS is a horizontal line, 100 mm in length, and anchored by word descriptors at each end. The VAS dyspnea score uses "no shortness of breath at all" and "maximum shortness of breath". The patient marks on the line the point that they feel represents the perception of their current state

Evaluation of Lungs conditionsChange from baseline, Every three days until patient's hospital discharge, up to 30 days

Anteroposterior chest radiography (CXR)

Oxygen saturationContinuosly, daily until patient's hospital discharge, up to 30 days

change in basal peripheral oxygen saturation percentage (%)

Secondary Outcome Measures
NameTimeMethod
lactate dehydrogenase (LDH)Daily until patient's hospital discharge, up to 30 days

Change in LDH. LDH is a marker of tissues damage. Units: Unites/L

Red blood cells countDaily until patient's hospital discharge, up to 30 days

Change in the number of red blood cells. Red blood cell count measure anemia. Units: million cells per microliter (cells/mcL)

Alanine transaminase (ALT)Daily until patient's hospital discharge, up to 30 days

Change in ALT. ALT is a liver function test. Units: mU/ml

Aspartate transaminase (AST)Daily until patient's hospital discharge, up to 30 days

Change in AST. AST ALT is a liver function test. Units : mU/ml

Mean Corpuscular Hemoglobin (MCH)Daily until patient's hospital discharge, up to 30 days

Change in the amount of hemoglobin per red blood cell. Mean cell hemoglobin is the average mass of hemoglobin per red blood cell in a sample of blood. Units: picograms (pg) per cell

Mean corpuscular volume (MCV)Daily until patient's hospital discharge, up to 30 days

change in the size of the red blood cells. Mean cell volume is a measure of the average volume of a red blood corpuscle. Units: femtoliters

beta - hydroxybutyrate (BHB)Daily until patient's hospital discharge, up to 30 days

Change in ketonemia measured as concentration of blood BHB Units: mmol/L

mean corpuscular hemoglobin concentration (MCHC)Daily until patient's hospital discharge, up to 30 days

change in the amount of hemoglobin per unit volume. Mean cell hemoglobin concentration is the average concentration of hemoglobin in a given volume of blood. Unites: g/dl of red blood cells

haemoglobin HbDaily until patient's hospital discharge, up to 30 days

change in total hemoglobin. Hemoglobin is an indirect way to measure red blood cells. Units: g/ dL

Trial Locations

Locations (1)

Ospedale San Bortolo

🇮🇹

Vicenza, Italy

© Copyright 2025. All Rights Reserved by MedPath